UniCAR02-T (IMP)
Sponsors
AvenCell Europe GmbH
Conditions
Acute Myeloid Leukemia (AML)Prostate Cancer
Phase 1
Phase 1 Study of UniCAR02-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies
TerminatedNCT04230265
Start: 2020-01-28End: 2025-04-11Updated: 2026-01-22
Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker
TerminatedNCT04633148
Start: 2020-11-23End: 2024-03-28Updated: 2024-04-23